Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Goldschmidt, Hartmut; Mai, Elias K.; Bertsch, Uta; Fenk, Roland; Nievergall, Eva; Tichy, Diana; Besemer, Britta; Durig, Jan; Schroers, Roland; von Metzler, Ivana; Haenel, Mathias; Mann, Christoph; Asemissen, Anne M.; Heilmeier, Bernhard; Weinhold, Niels; Huhn, Stefanie; Kriegsmann, Katharina; Luntz, Steffen P.; Holderried, Tobias A. W.; Trautmann-Grill, Karolin; Gezer, Deniz; Klaiber-Hakimi, Maika; Mueller, Martin; Khandanpour, Cyrus; Knauf, Wolfgang; Scheid, Christof; Munder, Markus; Geer, Thomas; Riesenberg, Hendrik; Thomalla, Jorg; Hoffmann, Martin; Raab, Marc S.; Salwender, Hans J.; Weisel, Katja C.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Autor(en):

Goldschmidt, Hartmut; Mai, Elias K.; Bertsch, Uta; Fenk, Roland; Nievergall, Eva; Tichy, Diana; Besemer, Britta; Durig, Jan; Schroers, Roland; von Metzler, Ivana; Haenel, Mathias; Mann, Christoph; Asemissen, Anne M.; Heilmeier, Bernhard; Weinhold, Niels; Huhn, Stefanie; Kriegsmann, Katharina; Luntz, Steffen P.; Holderried, Tobias A. W.; Trautmann-Grill, Karolin; Gezer, Deniz; Klaiber-Hakimi, Maika; Mueller, Martin; Khandanpour, Cyrus; Knauf, Wolfgang; Scheid, Christof; Munder, Markus; Geer, Thomas; Riesenberg, Hendrik; Thomalla, Jorg; Hoffmann, Martin; Raab, Marc S.; Salwender, Hans J.; Weisel, Katja C.

Tübinger Autor(en):

Besemer, Britta

Erschienen in:

Lancet Haematology (2022), Bd. 9, H. 11, S. E810-E821

Verlagsangabe:

Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

https://doi.org/10.1016/S2352-3026(22)00263-0

ISSN:

2352-3026